You are in: Home > News & Events > Research > Future Trials

Future Trials

Louise Coote Lupus Unit

Louise Coote Lupus Unit has a dedicated drugs trials team consisting of Professor D’Cruz DP, Dr Shirish R Sangle, and research nurse Lee Chung. Louise Nel will be joining the team as a research co-coordinator. Their team has an outstanding record of best recruitment in the UK in these trials including Benlysta (belimumab) and abatacept.

Future drug trials

  1. A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-Bä), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE) who completed the Phase 3 Protocol HGS1006-C1056 or HGS1006-C1057

  2. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE).

  3. Phase Iia, 2:2:1 randomised, double-blind, placebo-controlled, parellel group, multi-centre clinical trial to investigate the safety, efficacy and pharmacolkinetics of recombinant human soluble Fc-gamma receptor IIb (SM101) for intravenous application in the treatment of systemic lupus erythematosus (SLE) patients with or without a history of lupus nephritis.

  4. A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Systemic Lupus Erythematosus (SLE)

  5. A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-X)